# ELOXX PHARMACEUTICALS, INC. (ELOX) · Edgar & Edgarette company card

> Eloxx Pharmaceuticals (ELOX) saw revenue fall 100% in FY2025 to $0 million, operating margin null against a -15.8% median for biological products, (no diagnostic substances), equity -226% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1035354 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ELOX) · [JSON](https://www.pops4.com/boards/company/ELOX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | -100.0% |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -38.8%) |
| Net margin | -Infinity% |
| Operating cash flow | −$6M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $5M |
| Long-term debt | $1M |
| Total assets | $5M |
| Total equity | −$12M |
| Equity ÷ assets | -225.9% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -209.7 (distress zone)
- Piotroski F: 1 of 9 (weak)
- Health Harbor boat: Old boat · three warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025), total debt $1.0M. Experience: revenue down 100.0% on the year; operating margin null, down from -38.8%. Soundness: equity -225.9% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin null against a -15.8% median; growth -100.0% against 21.4%.

Range logged 2026-09-20, receipt 0c0deb1afe843f4f, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-10-22 ([filing](https://www.sec.gov/Archives/edgar/data/1035354/000119312526428116/0001193125-26-428116-index.htm))

## Recent filings

- 8-K · filed 2026-10-22 · 5.02 Departure or Election of Directors; Appointment of Officers; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1035354/000119312526428116/0001193125-26-428116-index.htm)
- S-1 · filed 2026-09-11 · [filing](https://www.sec.gov/Archives/edgar/data/1035354/000119312526389422/0001193125-26-389422-index.htm)
- 8-K · filed 2026-08-11 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1035354/000119312526345032/0001193125-26-345032-index.htm)
- 10-Q · filed 2026-08-11 · [filing](https://www.sec.gov/Archives/edgar/data/1035354/000119312526344964/0001193125-26-344964-index.htm)
- 8-K · filed 2026-06-01 · 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modifications to Rights of Security Holders; 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm)
- S-1 · filed 2026-05-07 · [filing](https://www.sec.gov/Archives/edgar/data/1035354/000119312526212324/0001193125-26-212324-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001035354.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1035354

## Cite

POPS4, Edgar & Edgarette: ELOXX PHARMACEUTICALS, INC. (ELOX) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/ELOX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.